Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity

Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the closing of a private placement, raising approximately $19.4 million by selling 24,341,607 shares of common stock at $0.622 each. Additionally, 272,970 shares of non-voting Class A-3 convertible preferred stock were sold at $6.22 per share. The proceeds will primarily support the advancement of RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease and for general corporate purposes. H.C. Wainwright and Co. acted as the exclusive placement agent for this financing.

Positive

• Raised approximately $19.4 million in private placement.
• Proceeds will primarily advance RGLS4326 for Autosomal Dominant Polycystic Kidney Disease.

Negative

• None.

LA JOLLA, Calif., Dec. 8, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced private placement of equity.  The Company received gross proceeds of approximately $19.4 million from the sale of 24,341,607 shares of the Company's common stock ("Common Stock") and accompanying warrants to purchase up to an aggregate of 18,256,204 shares of Common Stock at a purchase price of $0.622 per share of Common Stock and $0.125 for each share of Common Stock underlying such warrants.  In addition, the Company sold 272,970 shares of non-voting Class A-3 convertible preferred stock, in lieu of shares of Common Stock, at a price of $6.22 per share, and accompanying warrants to purchase an aggregate of  2,047,276 shares of Common Stock at a price of $0.125 for each share of Common Stock underlying these warrants.  Each share of non-voting Class A-3 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations.  The Company expects to use the net proceeds from the transaction primarily to advance RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease and for general corporate purposes.  H.C. Wainwright and Co. acted as exclusive placement agent for the financing. 

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

Additional details regarding the private placement are included in the Form 8-K filed with the Securities and Exchange Commission on December 4, 2020.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus maintains its corporate headquarters in La Jolla, CA. 

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Regulus's expected use of the net proceeds from the private placement.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of biopharmaceutical products and the Company's capital requirements. These and other risks are described in additional detail under the heading "Risk Factors" of the Company's Quarterly Report on 10-Q for the quarter ended September 30, 2020, filed with the Securities and Exchange Commission (SEC) on November 5, 2020, and Regulus's other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-announces-closing-of-19-4-million-private-placement-of-equity-301188135.html

SOURCE Regulus Therapeutics Inc.

FAQ

What is the significance of Regulus Therapeutics' recent private placement of equity?

The private placement raised approximately $19.4 million, which will be used to advance RGLS4326, targeting Autosomal Dominant Polycystic Kidney Disease.

How much did Regulus Therapeutics raise in the private placement?

Regulus Therapeutics raised approximately $19.4 million from the sale of common and convertible preferred stock.

Who acted as the placement agent for Regulus Therapeutics' financing?

H.C. Wainwright and Co. served as the exclusive placement agent for the financing.

What will Regulus Therapeutics use the proceeds from the private placement for?

The proceeds are expected to primarily support the development of RGLS4326 and for general corporate purposes.

What were the sale prices for shares and warrants in Regulus Therapeutics' private placement?

Shares of common stock were sold at $0.622 each, and warrants were priced at $0.125 each.